Unexpectedly, EBP2 antibodies were not boosted by P. vivax recurrent infections following antimalarial treatment; at the time of the outbreak, it was not possible to differentiate recrudescence due to therapeutic failures or relapses arising from persistent liver stages of the parasite (hypnozoites) [31]. Here, EBNA1BP2 is linked to infection.